Clinical trial NCT01021878: Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients
Official title: A Study to Evaluate the Effects of Icodextrin vs 2.5% Dianeal Used for the Long Dwell in Apd: a Randomized, Open-label Clinical Trial to Analyse the Insulin Resistance Using the Homa Index in Prevalent, Non-diabetic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Disorders Associated With Peritoneal Dialysis
Keywords: Peritoneal dialysis
Renal replacement therapy
Dialysis solutions
Icodextrin
Lead sponsor: Pontifícia Universidade Católica do Paraná
Sponsor class: OTHER
Collaborators: name: Baxter Healthcare Corporation
First posted: 2009-11-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1. LOCATION OF STUDY: Multicentric study in Brazil.
2. PURPOSE OF THE STUDY: To measure changes in HOMA index when non-diabetic patients in APD were exposed to 7,5% Icodextrin for the long-dwell; and to compare such changes with those produced by 2,5% glucose for the long-dwell.
3. PRIMARY OUTCOME: The primary efficacy outcome was to measure HOMA index to set the differences with regard to baseline values of this variable for the two groups as well as in each group, which showed control of the glucose metabolism.

STAGE OF THE STUDY : Phase IV postmarket study

DESIGN: Randomized, open-label, multicenter study. Patients were randomized to receive either to Extraneal (7,5% Icodextrin) or 2.5% Dianeal during the long-dwell.

SAMPLE SIZE: Randomization Upon completion of the study TOTAL: 120 60 ExtranealTM 60 30 Dianeal® 60 30

Duration: 1 year.

Detailed description: 1. SUMMARY OF THE STUDY

1.1 PROTOCOLE TITLE : A RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE EFFECTS OF ICODEXTRIN Vs 2,5% DIANEAL USED FOR THE LONG-DWELL ON HOMA INDEX IN PREVALENT, NON-DIABETIC, PATIENTS IN AUTOMATED PERITONEAL DIALYSIS (APD)

1.2 MAIN RESEARCHERS: Roberto Pecoits Filho, Thyago P. Moraes

1.3 LOCATION OF STUDY: Multicentric study in Brazil.

1.4 PURPOSE OF THE STUDY: To measure changes in HOMA index when non-diabetic patients in APD were exposed to 7,5% Icodextrin for the long-dwell; and to compare such changes with those produced by 2,5% glucose for the long-dwell.

1.5 PRIMARY OUTCOME: The primary efficacy outcome was to measure HOMA index to set the differences with regard to baseline values of this variable for the two groups as well as in each group, which showed control of the glucose metabolism.

1.6 SECONDARY OUTCOMES:

1.6.1 Other efficacy outcomes were total UF, long-dwell UF, and preprandial glycemia (taken first in the morning before breakfast), serum insulin levels and glycated haemoglobin.

1.6.2 The incidence of adverse events will be measured as a safety outcome.

1.7 STAGE OF THE STUDY : Phase IV postmarket study

1.8 DESIGN: Randomized, open-label, multicenter study. Patients were randomized to receive either to Extraneal (7,5% Icodextrin) or 2.5% Dianeal during the long-dwell.

1.9 SAMPLE SIZE: Randomization Upon completion of the study TOTAL: 100 60 ExtranealTM 50 30 Dianeal® 50 30

1.12 PHARMACEUTICAL FORM, ROUTE OF DE ADMINISTRATION AND DOSAGE

ExtranealTM (7.5% Icodextrin) solution for Peritoneal Dialysis:

It is labelled as "solution for dialysis" to be administered within the study for a period of one (1) year.

Available in 2 liter bags of peritoneal dialysis solution (Twin Bag) for CAPD, this product will be used during the long-dwell.

Dianeal® PD4 (2.5% Dextrose) solution for Peritoneal Dialysis:

It is labelled as 2.27% glucose-based "solution for dialysis", to be administered within the study for a period of one (1) year.

Available in 2 and 2.5 liter bags of peritoneal dialysis solution (Twin Bag) for CAPD, this product will be used during the long-dwell.

Duration: 1 year.

Eligibility criteria: Inclusion Criteria:

* 1.10.1 Older than 18 years old.
* High PET value, average-high or average-low.
* Cause of renal chronic disease other than diabetes mellitus.
* Patient in APD
* Prevalent patient in APD (defined as at least 90 total days of dialysis therapy)

Exclusion Criteria:

* Not willing to participate.
* A Charlson comorbidity index \>7, or a life expectancy \< 12 months as assessed by the treating physician.
* Positive VIH.
* Episodes of peritonitis during the month preceding the randomization.
* Significant cardiovascular, metabolic or infectious complications during the month preceding the randomization.
* Patients with active cancer.
* Patients with known allergies to corn starch polymers.
* Patients who are unable to provide an informed consent because of significant psychiatric disorder or mental illness
* Patients not meeting adequacy goals several months after the change in the dosage regime.

Primary outcomes:
measure: Adjusted HOMA Index Score at 3 Months Using Baseline Values as a Covariate and Groups as the Fixed Factor
timeFrame: 3 months
Secondary outcomes:
measure: Oral Fasting Serum Glucose
timeFrame: 3 months
measure: Serum Insulin
timeFrame: 3 months
measure: Glycated Hemoglobin
timeFrame: 3 months
measure: Total Ultrafiltration
timeFrame: 3 months
Other outcomes:
Locations:
city: Divinópolis
country: Brazil
facility: Hospital São João de Deus
state: MG
city: Uberlândia
country: Brazil
facility: Universidade Federal de Uberlândia
state: Minas Gerais
city: Curitiba
country: Brazil
facility: Instituto do Rim de Curitiba
state: Parana
city: Curitiba
country: Brazil
facility: Clinica de Doencas Renais
state: PR
city: Caxias do Sul
country: Brazil
facility: Nefroclinica de Caxias do Sul
state: Rio Grande do Sul
city: Botucatu
country: Brazil
facility: Universidade Estadual Paulista
state: Sao Paulo
city: Aracaju
country: Brazil
facility: Clinese
state: Sergipe
city: Sao Paulo
country: Brazil
facility: Universidade Federal de Sao Paulo
Study officials:
affiliation: Pontificia Universidade Catolica do Parana
name: Roberto Pecoits-Filho, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: